U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H25N3O7S
Molecular Weight 475.5167
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ERTAPENEM

SMILES

C[C@]1([H])[C@]2([H])[C@@]([H])([C@@]([H])(C)O)C(=O)N2C(=C1S[C@@]3([H])C[C@@]([H])(C(=Nc4cccc(c4)C(=O)O)O)NC3)C(=O)O

InChI

InChIKey=JUZNIMUFDBIJCM-ANEDZVCMSA-N
InChI=1S/C22H25N3O7S/c1-9-16-15(10(2)26)20(28)25(16)17(22(31)32)18(9)33-13-7-14(23-8-13)19(27)24-12-5-3-4-11(6-12)21(29)30/h3-6,9-10,13-16,23,26H,7-8H2,1-2H3,(H,24,27)(H,29,30)(H,31,32)/t9-,10-,13+,14+,15-,16-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including: https://www.drugs.com/ppa/ertapenem.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=33f3b99b-fa82-42e0-26bf-f49891ae3d22 | http://www.rxlist.com/invanz-drug.htm

Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichia coli, it has strong affinity toward PBPs 1a, 1b, 2, 3, 4 and 5 with preference for PBPs 2 and 3. Ertapenem has been designed to be effective against Gram-negative and Gram-positive bacteria. The most common drug-related adverse experiences in patients treated with INVANZ, including those who were switched to therapy with an oral antimicrobial, were diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%), and vomiting (1.1%). The coadministration with probenecid to extend the half-life of ertapenem is not recommended.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P0AD65
Gene ID: 945240.0
Gene Symbol: mrdA
Target Organism: Escherichia coli (strain K12)
Target ID: P0AD68
Gene ID: 944799.0
Gene Symbol: ftsI
Target Organism: Escherichia coli (strain K12)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Curative
INVANZ

Approved Use

To reduce the development of drug-resistant bacteria and maintain the effectiveness of INVANZ® and other antibacterial drugs, INVANZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment INVANZ is indicated for the treatment of adult patients and pediatric patients (3 months of age and older) with the following moderate to severe infections caused by susceptible isolates of the designated microorganisms [see Dosage and Administration (2)

Launch Date

1.00630082E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
75.7 μg/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
70.6 μg/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
155 μg/mL
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
663.1 ug/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
506.4 μg × h/mL
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
541.8 μg × h/mL
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
6225 ug*h/mL
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.5 h
1 g 1 times / day multiple, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: MULTIPLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
3.8 h
1 g single, intramuscular
dose: 1 g
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
4 h
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.3 h
1 g 3 times / week multiple, intravenous
dose: 1 g
route of administration: intravenous
experiment type: multiple
co-administered:
ERTAPENEM plasma
Homo sapiens
population: unhealthy
age:
sex:
food status:
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
1 g single, intravenous
dose: 1 g
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ERTAPENEM plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 1 times / day steady, intravenous
Highest studied dose
Dose: 3 g, 1 times / day
Route: intravenous
Route: steady
Dose: 3 g, 1 times / day
Sources:
healthy, 18-49 years
Health Status: healthy
Age Group: 18-49 years
Sex: M+F
Sources:
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Encephalopathy...
AEs leading to
discontinuation/dose reduction:
Encephalopathy (1 patient)
Sources:
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Disc. AE: Hallucinations, Delirium...
AEs leading to
discontinuation/dose reduction:
Hallucinations (1 patient)
Delirium (1 patient)
Sources:
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Disc. AE: Rash, Confusion...
AEs leading to
discontinuation/dose reduction:
Rash (1 patient)
Confusion (1 patient)
Seizure (1 patient)
Thrombocytopenia (1 patient)
Sources: Page: p. 184
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Other AEs: Diarrhea, Dizziness...
Other AEs:
Diarrhea (1 patient)
Dizziness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Encephalopathy 1 patient
Disc. AE
500 mg 1 times / day steady, intravenous (starting)
Dose: 500 mg, 1 times / day
Route: intravenous
Route: steady
Dose: 500 mg, 1 times / day
Co-administed with::
vancomycin(1250 mg intravenous loading dose followed by 500 mg intravenously once the following day)
Sources:
unhealthy, 59 years
n = 1
Health Status: unhealthy
Age Group: 59 years
Sex: M
Population Size: 1
Sources:
Delirium 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Hallucinations 1 patient
Disc. AE
1 g 1 times / day steady, intravenous
Recommended
Dose: 1 g, 1 times / day
Route: intravenous
Route: steady
Dose: 1 g, 1 times / day
Co-administed with::
daptomycin(1 g daily)
Sources:
unhealthy, 71 years
n = 1
Health Status: unhealthy
Condition: osteomyelitis
Age Group: 71 years
Sex: M
Population Size: 1
Sources:
Confusion 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Rash 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Seizure 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Thrombocytopenia 1 patient
Disc. AE
1 g 1 times / day steady, intravenous|intramuscular
Recommended
Dose: 1 g, 1 times / day
Route: intravenous|intramuscular
Route: steady
Dose: 1 g, 1 times / day
Sources: Page: p. 184
unhealthy, adult
n = 319
Health Status: unhealthy
Age Group: adult
Population Size: 319
Sources: Page: p. 184
Diarrhea 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Dizziness 1 patient
1 g 3 times / day single, intravenous
Overdose
Dose: 1 g, 3 times / day
Route: intravenous
Route: single
Dose: 1 g, 3 times / day
Sources:
healthy
n = 1
Health Status: healthy
Population Size: 1
Sources:
Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no [IC50 >500 uM]
no
no
no
yes [IC50 56.2 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
Gateways to Clinical Trials.
2002 Apr
Recent developments in carbapenems.
2002 Apr
In vitro activity of ertapenem (MK-0826) against multi-drug resistant Streptococcus pneumoniae compared with 13 other antimicrobials.
2002 Aug
Gateways to clinical trials.
2002 Jan-Feb
In vitro activity of ertapenem against bacterial isolates from cancer patients.
2002 Jul
A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults.
2002 Jul
Efficient one-pot synthesis of the 2-aminocarbonylpyrrolidin-4-ylthio-containing side chain of the new broad-spectrum carbapenem antibiotic ertapenem.
2002 Jul 12
Broad resistance due to plasmid-mediated AmpC beta-lactamases in clinical isolates of Escherichia coli.
2002 Jul 15
Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections.
2002 Jun
Comparative in vitro activities of ertapenem against aerobic and facultative bacterial pathogens from patients with complicated skin and skin structure infections.
2002 Jun
Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects.
2002 Mar
Use of surrogate antimicrobial agents to predict susceptibility to ertapenem.
2002 May
Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection.
2002 Nov
Modified high-performance liquid chromatographic method for the determination of ertapenem in human urine: enhanced selectivity and automation.
2002 Nov 5
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
2002 Oct
Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes.
2002 Oct
Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults.
2002 Sep
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
2002 Sep 1
Intra-abdominal anaerobic infections: bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents.
2002 Sep 1
[Efficacy of invanz proven in the treatment of intra-abdominal infections in one of the largest studies yet conducted on surgical patients].
2003
[New approaches to antibacterial therapy of infections in the surgical practice].
2003
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
2003
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
2003 May
Ertapenem, the first of a new group of carbapenems.
2003 Oct
Properties and potential of ertapenem.
2003 Sep
Newer treatment options for skin and soft tissue infections.
2004
Complicated infections of skin and skin structures: when the infection is more than skin deep.
2004 Jun
Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
2004 Jun
Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
2004 Jun
In vitro activity of ertapenem: review of recent studies.
2004 Jun
Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
2004 Jun
In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
2004 Jun
Gateways to clinical trials.
2004 Oct
Appropriate use of the carbapenems.
2004 Oct
Gateways to clinical trials.
2005 Apr
In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon.
2005 Apr
[Activity of ertapenem and 19 other antimicrobial agents against beta-lactam-resistant Streptococcus pneumoniae and Haemophilus influenzae respiratory tract isolates].
2005 Feb
Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery.
2005 Jun
Activity of three {beta}-lactams (ertapenem, meropenem and ampicillin) against intraphagocytic Listeria monocytogenes and Staphylococcus aureus.
2005 Jun
Gateways to clinical trials.
2005 Mar
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
2005 May
Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms.
2005 May
Patents

Sample Use Guides

1 g given once a day. Intravenous infusion for up to 14 days or intramuscular injection for up to 7 days.
Route of Administration: Other
The MICs of ertapenem are MIC(50) = 0.032 μg/ml; MIC(90) = 0.064 μg/ml in vitro activity of ertapenem against N.gonorrhoeae isolates.
Name Type Language
ERTAPENEM
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
(4R,5S,6S)-3-(((3S,5S)-5-((M-CARBOXYPHENYL)CARBAMOYL)-3-PYRROLIDINYL)THIO)-6-((1R)-1-HYDROXYETHYL)-4-METHYL-7-OXO-1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID
Systematic Name English
1-AZABICYCLO(3.2.0)HEPT-2-ENE-2-CARBOXYLIC ACID, 3-((5-(((3-CARBOXYPHENYL)AMINO)CARBONYL)-3-PYRROLIDINYL)THIO)-6-(1-HYDROXYETHYL)-4-METHYL-7-OXO-, (4R-(3(3S*,5S*), 4.ALPHA.,5.BETA.,6.BETA.(R*)))-
Systematic Name English
ERTAPENEM [MI]
Common Name English
ERTAPENEM [INN]
Common Name English
ERTAPENEM [VANDF]
Common Name English
ERTAPENEM [WHO-DD]
Common Name English
Classification Tree Code System Code
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000175496
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
WHO-ATC J01DH03
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NCI_THESAURUS C260
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
WHO-VATC QJ01DH03
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
NDF-RT N0000011294
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
LIVERTOX 366
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
Code System Code Type Description
FDA UNII
G32F6EID2H
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
LACTMED
Ertapenem
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
MESH
C446479
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
RXCUI
325642
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY RxNorm
EVMPD
SUB25388
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
DRUG CENTRAL
1046
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
MERCK INDEX
M5001
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB00303
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
HSDB
8020
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
CAS
153832-46-3
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
PUBCHEM
150610
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
NCI_THESAURUS
C61752
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
INN
8049
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
EPA CompTox
153832-46-3
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
ChEMBL
CHEMBL1359
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY
WIKIPEDIA
ERTAPENEM
Created by admin on Sat Jun 26 10:05:09 UTC 2021 , Edited by admin on Sat Jun 26 10:05:09 UTC 2021
PRIMARY